CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 82.67% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money
57.47
1.7%
Market Trading Hours* (UTC) Open now
Closes on Friday at 21:00

Mon - Fri: 14:30 - 21:00

  • Summary
  • Historical Data
Trading сonditions
Spread 0.34
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.024124 %
Charges from full value of position ($-0.24)
Trade size with leverage ~ $2,000.00
Money from leverage ~ $1,000.00

Go to platform
-0.024124%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.001901 %
Charges from full value of position ($0.02)
Trade size with leverage ~ $2,000.00
Money from leverage ~ $1,000.00

Go to platform
0.001901%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 50.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 56.57
Open 56.82
1-Year Change 58.14%
Day's Range 56.63 - 57.84
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Nov 21, 2024 56.57 -0.64 -1.12% 57.21 58.40 56.11
Nov 20, 2024 57.17 1.39 2.49% 55.78 57.21 55.27
Nov 19, 2024 55.74 3.43 6.56% 52.31 56.05 52.14
Nov 18, 2024 52.85 0.67 1.28% 52.18 53.70 51.48
Nov 15, 2024 52.39 -0.07 -0.13% 52.46 53.21 51.74
Nov 14, 2024 52.69 -1.78 -3.27% 54.47 55.41 52.46
Nov 13, 2024 55.43 0.44 0.80% 54.99 56.85 54.56
Nov 12, 2024 55.83 -0.21 -0.37% 56.04 57.49 55.55
Nov 11, 2024 56.73 3.73 7.04% 53.00 57.25 53.00
Nov 8, 2024 53.95 4.25 8.55% 49.70 54.33 49.45
Nov 7, 2024 49.97 1.04 2.13% 48.93 50.31 45.95
Nov 6, 2024 48.00 2.97 6.60% 45.03 48.68 45.03
Nov 5, 2024 44.72 0.66 1.50% 44.06 45.47 43.70
Nov 4, 2024 44.27 0.82 1.89% 43.45 44.57 43.45
Nov 1, 2024 43.94 -0.07 -0.16% 44.01 45.14 43.29
Oct 31, 2024 43.98 -1.38 -3.04% 45.36 45.38 43.49
Oct 30, 2024 45.47 0.38 0.84% 45.09 46.45 44.83
Oct 29, 2024 45.78 0.83 1.85% 44.95 45.78 44.63
Oct 28, 2024 45.57 1.61 3.66% 43.96 45.89 43.39
Oct 25, 2024 43.65 1.34 3.17% 42.31 44.36 42.31

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Vericel Corp Ord Company profile

About Vericel Corp

Vericel Corporation is a commercial-stage biopharmaceutical company. The Company specializes in cell therapies and specialty biologics for the sports medicine and severe burn care. It operates in one reportable segment, the research, product development, manufacture, and distribution of cellular therapies for use in the treatment of specific diseases. It markets two autologous cell therapy products in the United States, which includes MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The MACI is an autologous cellularized scaffold product indicated for the repair of symptomatic, single, or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. The Epicel is a permanent skin replacement humanitarian use device (HUD) for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns comprising greater than or equal to 30% of total body surface area (TBSA).

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Vericel Corp revenues increased 26% to $156.2M. Net loss totaled $7.5M vs. income of $2.9M. Revenues reflect MACI segment increase of 18% to $111.6M, Epicel segment increase of 51% to $41.5M. Net loss reflects Stock-based Compensation in SGA increase from $10M to $26.5M (expense), Other Selling , General Expense increase of 21% to $71.1M (expense).

Equity composition

Common Stock no Par, 3/11, 62.5M auth., 38,618,037 issd. Insiders control approx. 0.63%. IPO: 2/97, 3M shares @ $7 byCowen & Company. 02/10 1-for-8 reverse split. 10/13, 1-for-20 Reverse Stock split.

Industry: Biopharmaceuticals

64 Sidney St
CAMBRIDGE
MASSACHUSETTS 02139-4170
US

News

Gold bars on a black background with a diagram

Gold price predictions for the next five years: Third party data round up

Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.

15:17, 18 November 2024
SHIB cryptocurrency logo, showing a cartoon Shiba Inu dog on a coin, over a golden orange background with circuit board graphics detail

Shiba Inu coin price prediction 2030: could Shiba Inu coin reach $1? Third party price target

Can Shiba Inu reinvent itself to become a worthy long-term investment?

08:36, 15 November 2024

Trump trades charge as Bitcoin hits $US80,000

Bitcoin hits $80,000 amid expectations of fiscal stimulus, lower regulatory risks, and resilient US economy.

10:48, 13 November 2024

Australian jobs data expected to point to solid labour market conditions

Australian labour market and wage data to reveal job growth resilience, shaping RBA rate cut expectations and impacting AUD amidst global economic shifts.

10:16, 13 November 2024

FOMC cuts interest rates as expected and sticks to its line on future policy

The FOMC cut interest rates by 25 basis points at its November meeting, aligning with expectations. Wall Street hit record highs following the decision, with tech stocks leading the rally. Markets are pricing in a probable December cut amid resilient economic indicators.

13:33, 8 November 2024

FOMC and BOE preview: further rate cuts expected

Both the Federal Reserve and the Bank of England are expected to cut rates further when they meet later this week.

14:14, 5 November 2024

RBA meeting preview: No change to policy expected as inflation fight continues

The Reserve Bank of Australia is expected to keep its cash rate on hold at 4.35% when it announces its policy decision at 2.30PM on the 5th of November, 2024. Despite ongoing evidence of soft demand, upside risks to inflation are likely to remain the central bank’s primary concern.

13:35, 4 November 2024

People also watch

BTC/USD

97,538.70 Price
-0.540% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

XRP/USD

1.42 Price
+18.790% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 0.01168

Gold

2,690.21 Price
+0.820% 1D Chg, %
Long position overnight fee -0.0174%
Short position overnight fee 0.0092%
Overnight fee time 22:00 (UTC)
Spread 0.30

US100

20,715.60 Price
+0.180% 1D Chg, %
Long position overnight fee -0.0241%
Short position overnight fee 0.0019%
Overnight fee time 22:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 660,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading